Date: 2019-04-02

Type of information: Production agreement

Compound: large-scale AAV manufacturing

Company: Sangamo Therapeutics (USA - CA) Brammer Bio (USA - CA)

Therapeutic area:

Type agreement: manufacturing - production

Action mechanism: gene therapy



  • • On April 2, 2019, Sangamo Therapeutics announced it has signed an option agreement with Brammer Bio, a gene therapy contract development and manufacturing organization, to secure access to large-scale AAV manufacturing. Additionally, at Sangamo's new facilities in Brisbane, California, construction is underway of a Phase 1/2 cGMP manufacturing facility, which is expected to be operational in 2020.
  • The agreement with Brammer Bio provides Sangamo with access to dedicated AAV manufacturing capacity up to 2000-L bioreactor scale capable of handling large-scale, commercial -grade runs for products such as ST-920, Sangamo's gene therapy product candidate for Fabry disease. The agreement also allows Sangamo to leverage Brammer Bio's viral vector manufacturing know-how in the new Sangamo facility in Brisbane in order to provide a seamless transition from early development to late-stage clinical trials and commercial-scale manufacturing.

Financial terms:

Latest news:

Is general: Yes